Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oragenics Inc (OGEN)

Oragenics Inc (OGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,566
  • Shares Outstanding, K 12,213
  • Annual Sales, $ 40 K
  • Annual Income, $ -20,660 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 0.49
  • Price/Sales 97.70
  • Price/Cash Flow N/A
  • Price/Book 2.16
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.07
  • Most Recent Earnings $-0.38 on 11/13/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2542 +14.87%
on 11/19/24
0.4300 -32.09%
on 11/08/24
-0.0226 (-7.18%)
since 10/25/24
3-Month
0.2542 +14.87%
on 11/19/24
1.2900 -77.36%
on 08/30/24
-0.9780 (-77.01%)
since 08/27/24
52-Week
0.2542 +14.87%
on 11/19/24
7.7400 -96.23%
on 01/03/24
-3.2180 (-91.68%)
since 11/27/23

Most Recent Stories

More News
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

OGEN : 0.2920 (-3.95%)
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

OGEN : 0.2920 (-3.95%)
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

OGEN : 0.2920 (-3.95%)
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

/CNW/ -- A concussion is a mild traumatic brain injury temporarily disrupting the brain's normal function. Generally, concussions are induced by a blow or jolt...

OGEN : 0.2920 (-3.95%)
ABT : 118.95 (+0.84%)
BIIB : 159.83 (+1.36%)
PFE : 25.83 (+0.23%)
ABBV : 183.08 (+1.07%)
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

OGEN : 0.2920 (-3.95%)
ABT : 118.95 (+0.84%)
BIIB : 159.83 (+1.36%)
PFE : 25.83 (+0.23%)
ABBV : 183.08 (+1.07%)
CERE : 44.96 (+0.74%)
Oragenics to Participate in the World Vaccine Congress Washington

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive...

OGEN : 0.2920 (-3.95%)
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings from third party laboratory...

OGEN : 0.2920 (-3.95%)
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman...

OGEN : 0.2920 (-3.95%)
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has entered...

OGEN : 0.2920 (-3.95%)
Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has received...

OGEN : 0.2920 (-3.95%)

Business Summary

Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.

See More

Key Turning Points

3rd Resistance Point 0.3478
2nd Resistance Point 0.3339
1st Resistance Point 0.3129
Last Price 0.2920
1st Support Level 0.2780
2nd Support Level 0.2641
3rd Support Level 0.2431

See More

52-Week High 7.7400
Fibonacci 61.8% 4.8804
Fibonacci 50% 3.9971
Fibonacci 38.2% 3.1138
Last Price 0.2920
52-Week Low 0.2542

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar